← Back to Analyst Consensus 
LGND Buy
LIGAND PHARMACEUTICALS INC
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 25, 2026 | Barclays | initiate | — → Overweight | — | 53% |
| Sep 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 23, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 14, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Aug 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 6, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 3, 2026 | Oppenheimer | reiterate | Outperform → Outperform | — | 52% |
| Jul 15, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jul 9, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Jul 8, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| May 8, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Apr 30, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 28, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Apr 15, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Apr 14, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 24, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 11, 2026 | B of A Securities | initiate | — → Buy | — | 53% |
| Feb 27, 2026 | Oppenheimer | maintain | Outperform → Outperform | $277 | 52% |
| Feb 24, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $239 | 44% |
| Dec 10, 2025 | RBC Capital | maintain | Outperform → Outperform | $235 | 55% |
| Dec 10, 2025 | Stifel | maintain | Buy → Buy | $230 | 53% |
| Dec 9, 2025 | Citigroup | initiate | — → Buy | $270 | 54% |
| Nov 10, 2025 | RBC Capital | maintain | Outperform → Outperform | $234 | 55% |
| Nov 7, 2025 | Benchmark | maintain | Buy → Buy | $220 | 54% |
| Nov 7, 2025 | Oppenheimer | maintain | Outperform → Outperform | $275 | 52% |
| Nov 6, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $231 | 44% |
| Nov 3, 2025 | Oppenheimer | maintain | Outperform → Outperform | $250 | 52% |
| Sep 3, 2025 | Oppenheimer | maintain | Outperform → Outperform | $190 | 52% |
| Sep 2, 2025 | Benchmark | maintain | Buy → Buy | $175 | 54% |
| Aug 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $206 | 44% |
| Aug 8, 2025 | RBC Capital | maintain | Outperform → Outperform | $185 | 55% |
| Aug 7, 2025 | Oppenheimer | maintain | Outperform → Outperform | $167 | 52% |
| Jul 30, 2025 | Oppenheimer | maintain | Outperform → Outperform | $162 | 52% |
| May 9, 2025 | Oppenheimer | maintain | Outperform → Outperform | $145 | 52% |
| Apr 10, 2025 | Stifel | initiate | — → Buy | $143 | 53% |
| Dec 23, 2024 | Benchmark | reiterate | Buy → Buy | $135 | 54% |
| Dec 16, 2024 | Barclays | maintain | Overweight → Overweight | $160 | 53% |
| Dec 11, 2024 | RBC Capital | maintain | Outperform → Outperform | $143 | 55% |
| Dec 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $0 | 44% |
| Nov 12, 2024 | RBC Capital | maintain | Outperform → Outperform | $140 | 55% |
| Nov 8, 2024 | Benchmark | maintain | Buy → Buy | $135 | 54% |
| Nov 8, 2024 | Barclays | maintain | Overweight → Overweight | $150 | 53% |
| Nov 8, 2024 | Oppenheimer | maintain | Outperform → Outperform | $147 | 52% |
| Nov 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $157 | 44% |
| Oct 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $157 | 44% |
| Oct 28, 2024 | Barclays | maintain | Overweight → Overweight | $125 | 53% |
| Oct 21, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $157 | 44% |
| Oct 3, 2024 | Oppenheimer | initiate | — → Outperform | $135 | 52% |
| Aug 12, 2024 | Benchmark | maintain | Buy → Buy | $110 | 54% |
| Aug 12, 2024 | RBC Capital | reiterate | Outperform → Outperform | $130 | 55% |
Price Target Trend
Jun 15, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days